Dencichine ameliorates hepatic fibrosis by modulating the PI3K/AKT signaling pathway in cellular and murine models
- 1Department of Pharmacy, The Third Affiliated Hospital of Guizhou Medical University
- 2Medical Experimental Center, The Third Affiliated Hospital of Guizhou Medical University
- 3Department of Infectious Diseases, The Third Affiliated Hospital of Guizhou Medical University
Abstract
Background: Fibrotic liver is one of the serious pathophysiological consequences of chronic injury to the liver, may progress toward serious complications including cirrhosis and hepatic carcinoma. Objectives: Panax notoginseng is used for both therapeutic and prophylactic purposes in TCM; it is a source of Dencichine, an active substance that has been proven to exhibit antifibrotic properties in hepatic fibrosis. The present study investigated how Dencichine treatment ameliorates liver fibrosis using an animal model and a cellular fibrosis model. Methods: Randomly assigned, male C57BL/6J mice received 10% CCl4 for 15 consecutive weeks to induce hepatic fibrosis. Treatment with Dencichine was initiated from 7th week onward. To simulate in-vitro the presence of a fibrotic microenvironment, LX-2 cells were treated with PDGF-BB at a concentration of 20 ng/mL and incubated from one up to four days and then treated by various doses of Dencichine. Liver function was evaluated by measuring alanine aminotransferase (ALT), AST, HA and LN. Histopathology was evaluated by haematoxylin/eosin (HE), Masson’s trichrome and Sirius red stains. Quantitative real-time PCR and western blot analyses were used to evaluate mRNA and protein expression levels, respectively. Wound-healing assays and transwell chamber experiments were used to assess cell migration; EdU proliferation detection and flow cytometry were performed to measure cell proliferation and cell cycle, respectively. Results: The most important results are a considerable reduction of serum concentrations of AST and ALT, HA and laminin in CCl4-treated mice decreased liver injury and ECM deposition. Furthermore, this compound downregulated the expression of cyclin D1 and cyclin E1 and blocked the activation of PI3K and AKT kinases in fibrotic liver cells. Conclusion: These results indicate that Dencichine may slow the development of liver fibrosis by interfering with the PI3K-AKT signaling cascade, demonstrating significant anti-scarring properties.
Related
- Single-cell RNA Sequencing Analysis Reveals That Targeting PLG–PLGRKT Signaling-mediated Pro-fibrotic Scar-associated Macrophages Ameliorates Liver Fibrosis in Biliary Atresia
- Quercetin ameliorates gestational diabetes mellitus-induced placental dysfunction by modulating the AGE-RAGE-associated oxidative and inflammatory signaling network
- Xinfeng capsule regulates pyroptosis and ameliorates cardiac fibrosis in rheumatoid arthritis through lncRNA GAS5 and TLR4/ROS/miR-21 pathways
- A Bi-Adjuvant Senolytic Nanovaccine Modulating Dendritic Cell Senescence Ameliorates Aging-Related Metabolic Dysfunction.
- L-(+)-Ergothioneine ameliorates preeclampsia-associated vascular endothelial dysfunction by modulating the Nrf2-PPARγ-sFlt-1 axis
BibTeX
@article{li2026dencichine,
title = {{Dencichine ameliorates hepatic fibrosis by modulating the PI3K/AKT signaling pathway in cellular and murine models}},
author = {Longkuan Li and Lixian Mo and Huan Luo and Zeyun Liu and Wei Zhang and Jinyou Tian and Fuxue Meng and Yingqiang Chen},
journal = {Pakistan Journal of Pharmaceutical Sciences},
year = {2026},
month = oct,
doi = {10.36721/pjps/2026.40.16394.1},
url = {https://doi.org/10.36721/pjps/2026.40.16394.1},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Dencichine ameliorates hepatic fibrosis by modulating the PI3K/AKT signaling pathway in cellular and murine models
AU - Longkuan Li
AU - Lixian Mo
AU - Huan Luo
AU - Zeyun Liu
AU - Wei Zhang
AU - Jinyou Tian
AU - Fuxue Meng
AU - Yingqiang Chen
PY - 2026
DA - 2026/10/31
JO - Pakistan Journal of Pharmaceutical Sciences
DO - 10.36721/pjps/2026.40.16394.1
UR - https://doi.org/10.36721/pjps/2026.40.16394.1
AB - Background: Fibrotic liver is one of the serious pathophysiological consequences of chronic injury to the liver, may progress toward serious complications including cirrhosis and hepatic carcinoma. Objectives: Panax notoginseng is used for both therapeutic and prophylactic purposes in TCM; it is a source of Dencichine, an active substance that has been proven to exhibit antifibrotic properties in hepatic fibrosis. The present study investigated how Dencichine treatment ameliorates liver fibrosis using an animal model and a cellular fibrosis model. Methods: Randomly assigned, male C57BL/6J mice received 10% CCl4 for 15 consecutive weeks to induce hepatic fibrosis. Treatment with Dencichine was initiated from 7th week onward. To simulate in-vitro the presence of a fibrotic microenvironment, LX-2 cells were treated with PDGF-BB at a concentration of 20 ng/mL and incubated from one up to four days and then treated by various doses of Dencichine. Liver function was evaluated by measuring alanine aminotransferase (ALT), AST, HA and LN. Histopathology was evaluated by haematoxylin/eosin (HE), Masson’s trichrome and Sirius red stains. Quantitative real-time PCR and western blot analyses were used to evaluate mRNA and protein expression levels, respectively. Wound-healing assays and transwell chamber experiments were used to assess cell migration; EdU proliferation detection and flow cytometry were performed to measure cell proliferation and cell cycle, respectively. Results: The most important results are a considerable reduction of serum concentrations of AST and ALT, HA and laminin in CCl4-treated mice decreased liver injury and ECM deposition. Furthermore, this compound downregulated the expression of cyclin D1 and cyclin E1 and blocked the activation of PI3K and AKT kinases in fibrotic liver cells. Conclusion: These results indicate that Dencichine may slow the development of liver fibrosis by interfering with the PI3K-AKT signaling cascade, demonstrating significant anti-scarring properties.
SN - 1011-601X
SN - 3105-9686
ER -